Australian biotechnology company AdAlta (ASX:1AD) has expanded the clinical advisory board of its subsidiary AdCella as it prepares to advance a promising new CAR-T cell therapy for solid cancers into further development and clinical testing. …
AdAlta strengthens clinical push for breakthrough solid cancer therapy
March 4, 2026 Australian Biotech
Latest Video
New Stories
-
ARCS launches national partnership to boost public clinical research sites
May 27, 2026 - - Latest News -
Australia’s access dilemma and how commercial leaders have adapted over time
May 27, 2026 - - Latest News -
TGA approves Sanofi innovation that offers the chance to delay onset of type 1 diabetes
May 27, 2026 - - Latest News -
This unique historical oddity says all we need to know about the institution
May 26, 2026 - - Latest News -
New Zealand's Pharmac consulting on new vaccine brands and wider flu access for young children
May 26, 2026 - - Latest News -
New national survey reveals muscle health screening gap in Australian general practice
May 26, 2026 - - Latest News -
Mayne Pharma awarded legal costs as business expansion gains momentum
May 25, 2026 - - Latest News